drugset / Trial / NCT04842032
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH
Timeline
- Start
- 2021-11-01
- Primary completion
- 2023-12-18
- Completion
- 2023-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burosumab | Monoclonal antibody | 0.8 mg/kg | Subcutaneous |